Prostate Radiotherapy in India: Evolution, Practice and Challenges in the 21st Century

Murthy, Vedang; Mallick, Indranil; Arunsingh, Moses; Gupta, Pooja

doi:10.1016/j.clon.2019.05.020

Cited by 15 publications

(9 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, prostate BT in clinical practice has never been successful in Indian cancer hospitals [ 12 ]. Therefore, we wanted to understand the practice of ISBT in India and the attitude of Indian radiation oncologists towards prostate BT.…”

Section: Purposementioning

confidence: 99%

Current status and future readiness of Indian radiation oncologists to embrace prostate high-dose-rate brachytherapy: An Indian Brachytherapy Society survey

Banerjee,

Sarkar,

Mahantshetty

et al. 2023

jcb

View full text Add to dashboard Cite

Purpose This survey aimed to understand the practice pattern and attitude of Indian doctors towards prostate brachytherapy. Material and methods A 21-point questionnaire was designed in Google form and sent to radiation oncologists practicing in India, using texts, mails, and social media. Responses were collated, and descriptive statistical analysis was performed. Results A total of 212 radiation oncologists from 136 centers responded to the survey questionnaire, with majority (66%) being post-specialty training > 6 years. We found that about 44.3% ( n = 94) of respondents do not practice interstitial brachytherapy for any site, and majority (83.3%, n = 175) do not practice high-dose-rate (HDR) prostate brachytherapy. Only 2.8% ( n = 6) of doctors preferred boost by brachytherapy compared with 38.1% ( n = 80) of respondents, who favored stereotactic body radiation therapy (SBRT) boost. When asked about the indication of HDR prostate brachytherapy in Indian setting, 32.5% ( n = 67) of respondents favored monotherapy, 46.1% ( n = 95) of oncologists thought boost as a good indication, and 21.4% ( n = 44) preferred re-irradiation/salvage setting. The most cited reason for prostate brachytherapy not being popularly practiced in India was lack of training (84.8%, n = 179). It was also noted that out of 80 respondents who practiced SBRT for prostate boost, 37 would prefer HDR brachytherapy boost if given adequate training and facilities. Conclusions The present survey provided insight on practice of prostate brachytherapy in India. It is evident that majority of radiation oncologists do not practice HDR prostate brachytherapy due to lack of training and infrastructure. Indian physicians are willing to learn and start prostate brachytherapy procedures if dedicated training and workshops are organized.

show abstract

Section: Purposementioning

confidence: 99%

Current status and future readiness of Indian radiation oncologists to embrace prostate high-dose-rate brachytherapy: An Indian Brachytherapy Society survey

Banerjee,

Sarkar,

Mahantshetty

et al. 2023

jcb

View full text Add to dashboard Cite

show abstract

“…Investing in a cobalt source, which has a much longer half-life than an iridium source, could also reduce the long-term costs associated with brachytherapy (102e103). Also, LDR brachytherapy seeds for prostate cancer are not available in India (104). The Government of India has recently planned a plant for the manufacture of I-125 seeds (105).…”

Section: Brachytherapy Equipment and Infrastructurementioning

confidence: 99%

Brachytherapy in India: Learning from the past and looking into the future

et al. 2020

View full text Add to dashboard Cite

“…Prostate cancer is the second most common cancer among men globally and the second most common cause of cancer-related mortality [1,2]. In India, it is the third most common cancer [3]. Notably, despite the low overall incidence of prostate cancer in India, the associated mortality is relatively high as compared to those of other countries with higher incidence rates [3].…”

Section: Introductionmentioning

confidence: 99%

“…In India, it is the third most common cancer [3]. Notably, despite the low overall incidence of prostate cancer in India, the associated mortality is relatively high as compared to those of other countries with higher incidence rates [3]. Moreover, the incidence of new prostate cancer cases in India is estimated to increase from 34,500 in 2020 to 65,100 in 2040 [4].…”

Section: Introductionmentioning

confidence: 99%

Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus

Desai¹,

Vaid

Biswas

et al. 2022

Oncol Ther

View full text Add to dashboard Cite

Introduction: With the availability of an increasing number of therapeutic options for advanced prostate cancer (APC), optimal sequencing and combination of therapies have emerged to be the areas of challenges. In the Indian context, there is a dearth of consensus recommendations to guide clinicians regarding optimal sequencing of therapy in APC management. A Delphi-based consensus regarding optimal therapy sequencing in APC management was developed by an expert panel of medical oncologists from across India.Methods: An expert scientific committee of 11 medical oncologists and an expert panel of 53 medical oncologists from India constituted the panel for the Delphi consensus. In the first phase, a questionnaire with 41 clinical statements was developed in several critical controversial areas in APC treatment. In the second phase, 29 clinical statements were reworked and sent to eight experts to obtain their opinions on best practices. The consensus ratings were based on a 9-point Likert scale. Based on the overall response, statements with a mean score of C 7 with 1 outlier were considered as ''consensus.'' Results: Degarelix was the preferred androgen deprivation therapy (ADT). While ADT plus

show abstract

Prostate Radiotherapy in India: Evolution, Practice and Challenges in the 21st Century

Cited by 15 publications

References 50 publications

Current status and future readiness of Indian radiation oncologists to embrace prostate high-dose-rate brachytherapy: An Indian Brachytherapy Society survey

Current status and future readiness of Indian radiation oncologists to embrace prostate high-dose-rate brachytherapy: An Indian Brachytherapy Society survey

Brachytherapy in India: Learning from the past and looking into the future

Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus

Contact Info

Product

Resources

About